(LNTH) Lantheus Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5165441032
LNTH: Diagnostic Imaging Agents, Radiopharmaceuticals, Therapeutic Products
Lantheus Holdings Inc (NASDAQ:LNTH) stands out as a leader in the medical diagnostics and therapeutics sector, with a strong focus on cardiovascular and cancer applications. Their product portfolio includes DEFINITY, an ultrasound enhancer for echocardiography, and TechneLite, a technetium generator crucial for nuclear medicine. Additionally, they offer Xenon-133 for pulmonary function assessment and Neurolite for stroke diagnosis, showcasing their commitment to diverse diagnostic needs.
The companys innovation extends to AI-driven solutions like aPROMISE and PYLARIFY AI, enhancing diagnostic accuracy and efficiency. Their R&D pipeline is robust, featuring therapies such as PNT2002 for prostate cancer and MK-6240 targeting Alzheimers, indicating a strategic focus on future growth areas. Collaborations with industry giants like GE Healthcare and Regeneron underscore their commitment to cutting-edge advancements.
Financially, Lantheus presents a compelling profile with a market cap of $6.45 billion and a P/E ratio of 15.41, suggesting a balanced valuation. Their P/S ratio of 4.31 highlights strong revenue generation, positioning them attractively for investors seeking exposure to the growing diagnostics and precision medicine sectors.
In conclusion, Lantheuss strategic positioning, diverse product range, and innovative pipeline make it a standout investment opportunity in the healthcare industry. Their focus on precision medicine aligns with market trends, offering promising growth potential for investors.
Additional Sources for LNTH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LNTH Stock Overview
| Market Cap in USD | 5,558m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2015-06-25 |
LNTH Stock Ratings
| Growth 5y | 85.5% |
| Fundamental | 86.9% |
| Dividend | 0.0% |
| Rel. Strength Industry | 38 |
| Analysts | 4.62/5 |
| Fair Price Momentum | 89.66 USD |
| Fair Price DCF | 54.95 USD |
LNTH Dividends
No Dividends PaidLNTH Growth Ratios
| Growth Correlation 3m | 4.9% |
| Growth Correlation 12m | 57.1% |
| Growth Correlation 5y | 89.4% |
| CAGR 5y | 38.04% |
| CAGR/Max DD 5y | 0.78 |
| Sharpe Ratio 12m | 0.80 |
| Alpha | 26.52 |
| Beta | 0.59 |
| Volatility | 53.03% |
| Current Volume | 880.3k |
| Average Volume 20d | 835.4k |
As of February 21, 2025, the stock is trading at USD 80.84 with a total of 880,346 shares traded.
Over the past week, the price has changed by -1.37%, over one month by -14.05%, over three months by -6.49% and over the past year by +42.25%.
Yes, based on ValueRay Fundamental Analyses, Lantheus Holdings (NASDAQ:LNTH) is currently (February 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.85 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LNTH as of February 2025 is 89.66. This means that LNTH is currently undervalued and has a potential upside of +10.91% (Margin of Safety).
Lantheus Holdings has received a consensus analysts rating of 4.62. Therefor, it is recommend to buy LNTH.
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, LNTH Lantheus Holdings will be worth about 106.7 in February 2026. The stock is currently trading at 80.84. This means that the stock has a potential upside of +31.94%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 133.2 | 64.8% |
| Analysts Target Price | 134.7 | 66.6% |
| ValueRay Target Price | 106.7 | 31.9% |